KR20150036710A - 낮은 푸코실화를 갖는 항-her2 항체를 이용한 신규한 치료적 처리 - Google Patents

낮은 푸코실화를 갖는 항-her2 항체를 이용한 신규한 치료적 처리 Download PDF

Info

Publication number
KR20150036710A
KR20150036710A KR20157004250A KR20157004250A KR20150036710A KR 20150036710 A KR20150036710 A KR 20150036710A KR 20157004250 A KR20157004250 A KR 20157004250A KR 20157004250 A KR20157004250 A KR 20157004250A KR 20150036710 A KR20150036710 A KR 20150036710A
Authority
KR
South Korea
Prior art keywords
her2
antibody
her2 antibody
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157004250A
Other languages
English (en)
Korean (ko)
Inventor
슈테펜 고레츠
안티예 다니엘치크
Original Assignee
글리코토페 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리코토페 게엠베하 filed Critical 글리코토페 게엠베하
Publication of KR20150036710A publication Critical patent/KR20150036710A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR20157004250A 2012-07-18 2013-07-18 낮은 푸코실화를 갖는 항-her2 항체를 이용한 신규한 치료적 처리 Withdrawn KR20150036710A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261673216P 2012-07-18 2012-07-18
US201261673229P 2012-07-18 2012-07-18
US201261673201P 2012-07-18 2012-07-18
US61/673,229 2012-07-18
US61/673,201 2012-07-18
US61/673,216 2012-07-18
EP12197768 2012-12-18
EP12197768.0 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (en) 2012-07-18 2013-07-18 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
KR20150036710A true KR20150036710A (ko) 2015-04-07

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157004250A Withdrawn KR20150036710A (ko) 2012-07-18 2013-07-18 낮은 푸코실화를 갖는 항-her2 항체를 이용한 신규한 치료적 처리

Country Status (16)

Country Link
US (1) US20150166664A1 (cg-RX-API-DMAC10.html)
EP (1) EP2874658A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015528802A (cg-RX-API-DMAC10.html)
KR (1) KR20150036710A (cg-RX-API-DMAC10.html)
CN (1) CN104394887A (cg-RX-API-DMAC10.html)
AU (1) AU2013291964B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014032169A2 (cg-RX-API-DMAC10.html)
CA (1) CA2875486A1 (cg-RX-API-DMAC10.html)
EA (1) EA201590237A1 (cg-RX-API-DMAC10.html)
IL (1) IL236714A0 (cg-RX-API-DMAC10.html)
MA (1) MA37961A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015000730A (cg-RX-API-DMAC10.html)
NZ (1) NZ701974A (cg-RX-API-DMAC10.html)
SG (1) SG11201407841YA (cg-RX-API-DMAC10.html)
WO (1) WO2014013019A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201408938B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
JP7273858B2 (ja) * 2018-06-15 2023-05-15 シャンハイ ミラコーケン インコーポレイティド 癌を治療するための方法と材料
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用
CN116942809A (zh) * 2023-03-03 2023-10-27 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2026158510A1 (zh) * 2025-01-24 2026-07-30 百奥泰生物制药股份有限公司 治疗实体瘤的联合疗法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
KR101498588B1 (ko) * 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
MX2012004029A (es) * 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Also Published As

Publication number Publication date
AU2013291964B2 (en) 2017-12-14
AU2013291964A1 (en) 2015-02-05
ZA201408938B (en) 2016-09-28
NZ701974A (en) 2018-03-23
WO2014013019A1 (en) 2014-01-23
EP2874658A1 (en) 2015-05-27
BR112014032169A2 (pt) 2017-08-01
US20150166664A1 (en) 2015-06-18
SG11201407841YA (en) 2015-02-27
MX2015000730A (es) 2015-08-06
MA37961A1 (fr) 2016-06-30
EA201590237A1 (ru) 2015-05-29
IL236714A0 (en) 2015-02-26
CA2875486A1 (en) 2014-01-23
CN104394887A (zh) 2015-03-04
JP2015528802A (ja) 2015-10-01

Similar Documents

Publication Publication Date Title
US20160068609A1 (en) Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
KR102749931B1 (ko) 암 치료에서 화학요법제와 병용되는 항-fgfr2 항체
JP2024079823A (ja) ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体
AU2013291964B2 (en) Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation
TWI870335B (zh) 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
KR20170070076A (ko) 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
CN119569881B (zh) 抗cd39抗体及其用途
US20210070862A1 (en) B7-h4 antibody dosing regimens
KR102744809B1 (ko) 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
AU2022267362A1 (en) Anti-siglec compositions and uses thereof
CN105849125A (zh) 神经调节蛋白变构抗her3抗体
JP2026083251A (ja) 少なくともｅｇｆｒに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いｅｇｆｒ発現を有するがんの治療
CN111032081A (zh) ErbB-2和ErbB-3靶向剂和双特异性抗体
US20250282865A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPa ANTIBODY
US20260000760A1 (en) Triple combination cancer therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
CA3252302A1 (en) Combination of antibody-drug conjugate and anti-sirp.alpha. antibody
JP2024509944A (ja) 抗体の新規の組み合わせ及びその使用
HK40117039A (en) Combination of antibody-drug conjugate and anti-sirpalpha antibody
HK40027719A (en) Erbb-2 and erbb-3 targeting agent and bispecific antibody
EA052461B1 (ru) Агент, нацеленный на erbb-2, и биспецифическое антитело с сайтами связывания антигена, которые связывают эпитоп на внеклеточной части erbb-2 и erbb-3, для лечения индивида с положительной по erbb-2, erbb-3 или erbb-2/3 опухолью

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid